Table 1 Demographic characteristics of the patients enrolled in the cross-sectional study
From: The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19
Beijing | Tianjin | Wuhan | Shijiazhuang | Sum | P value | ||
|---|---|---|---|---|---|---|---|
COVID-19 confirmed patients | Cases | 12 | 127 | 29 | 67 | 235 | – |
average interval from onset to sampling (days) | 3.3 | 10.4 | 20.9 | 13.5 | – | – | |
Age | 40.0 (34.0,63.0) | 49.0 (36.0,61.0) | 61.0 (46.5,69.0) | 44.0 (34.0,65.0) | 49.0 (35.0,64.0) | 0.048 | |
Male | 5 (41.7%) | 64 (50.4%) | 16 (55.2%) | 45 (67.2%) | 130 (55.3%) | 0.114 | |
seroprevalence of IgG | 75.0% | 95.3% | 75.9% | 95.5% | 91.9% | < 0.001 | |
seroprevalence of IgM | 75.0% | 95.3% | 75.9% | 97.0% | 92.3% | < 0.001 | |
Suspected patients | Cases | 132 | 20 | – | 184 | 336 | – |
Age | 45.5 (29.0,63.0) | 63.5 (50.8,70.8) | – | 33.0 (26.0,44.0) | 37.0 (28.8,56.0) | < 0.001 | |
Male | 61 (46.2%) | 12 (60.0%) | – | 96 (59.8%) | 183 (54.5%) | 0.051 | |
seroprevalence of IgG | 3.8% | 0.0% | – | 1.1% | 2.1% | < 0.001 | |
seroprevalence of IgM | 13.1% | 0.0% | – | 0.5% | 5.4% | < 0.001 |